JERSEY CITY, N.J.--(BUSINESS WIRE)--Quantum Genomics Corp. (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, today announced a strategic agreement for the manufacture of the first batch of its QCC001 drug candidate for hypertension. The agreement is with PCAS Pharma Synthesis, a world-class supplier of key intermediates and bulk actives to the pharmaceutical industry.
